Cerebroprotein Hydrolysate

CPH, cerebroprotein hydrolysate injection, 'Cerebrolysin' (mislabelled by some vendors)

Cerebroprotein Hydrolysate (CPH, cerebroprotein hydrolysate injection, 'Cerebrolysin' (mislabelled by some vendors)) is a cognitive & mood research compound. A porcine brain-derived peptide preparation: brain tissue is enzymatically digested and filtered to leave low-molecular-weight peptides and free amino acids. The proposed action is neurotrophic — the peptide fraction is claimed to mimic the effect of endogenous neurotrophic factors such as BDNF, GDNF and NGF, which are themselves far too large to cross the blood-brain barrier. Small peptides that survive digestion are the proposed messengers.

How Cerebroprotein Hydrolysate works

A porcine brain-derived peptide preparation: brain tissue is enzymatically digested and filtered to leave low-molecular-weight peptides and free amino acids. The proposed action is neurotrophic — the peptide fraction is claimed to mimic the effect of endogenous neurotrophic factors such as BDNF, GDNF and NGF, which are themselves far too large to cross the blood-brain barrier. Small peptides that survive digestion are the proposed messengers.

Proposed benefits

Studied for cognitive impairment, stroke recovery and traumatic brain injury — the same territory as Cerebrolysin, but it is not the same product.

Where to get Cerebroprotein Hydrolysate

The evidence for Cerebroprotein Hydrolysate

Graded by what exists behind each claim.

✅ Clinically validated

• Randomized trials exist, largely from China and India, in acute stroke, traumatic brain injury and vascular cognitive impairment, generally reporting modest improvement on cognitive scales against standard care. This is a separate evidence base from Cerebrolysin's — different manufacturers, different preparations, and the two are routinely conflated in marketing because the products are cousins.
• Quality is mixed: many trials are small, single-center, open-label, and published in journals that Western reviewers do not commonly index. That is a reason for caution about effect size, not proof of absence.

📊 Correlative data

• Used clinically in several Asian markets as an IM or slow-IV course, typically 10-20 days. Practitioner reports center on cognition and recovery after neurological insult rather than on enhancement in healthy people, which is the population most research buyers belong to and the one nobody has studied.

🧪 Theoretical / extrapolated

• Porcine brain tissue is enzymatically digested and filtered to leave low-molecular-weight peptides and free amino acids. The proposal is that these fragments act as neurotrophic mimetics — standing in for BDNF, GDNF and NGF, which are far too large to cross the blood-brain barrier.
• The format is how you tell it apart from Cerebrolysin, and it matters for dosing. Cerebrolysin is a standardized LIQUID ampoule concentrate dosed in milliliters; cerebroprotein hydrolysate is a LYOPHILIZED powder dosed in milligrams. Several research vendors list a 30mg lyophilized vial under the name 'Cerebrolysin' — that product is this one. A protocol written for one cannot be converted to the other, because the peptide profiles are not the same and neither is standardized against the other.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What Cerebroprotein Hydrolysate actually does

Read this product's own literature and it defines itself in the words you would use to define Cerebrolysin. Cerebroprotein Hydrolysate-I is ‘a neuropeptide preparation which consists of several amino acids and small molecular peptides’ Wu 2021, and ‘a mixture of hydrolyzed peptides and amino acids’ Zhang 2024. Porcine brain protein, enzymatically digested, filtered to the low-molecular-weight fraction. That is the same manufacturing definition, the same source tissue and the same claimed mechanism as the product sold under the other name.

So the direct answer, because a page that dodged it would be worth less than no page. Cerebrolysin and cerebroprotein hydrolysate are the same class of preparation under two names, and the phrase ‘cerebroprotein hydrolysate’ functions in this literature as the generic description of that class rather than as a trade name. What has not been shown is that they are the same product. Different manufacturers, different physical formats, and — the part that settles nothing and is usually presented as if it settled everything — two trial bases that never cite each other. No compositional comparison of the two has ever been published. Anyone telling you confidently that they are identical, and anyone telling you confidently that they are unrelated, is stating a preference rather than a measurement.

What the difference definitely is: units. Cerebrolysin is a liquid concentrate dosed in milliliters. This is a lyophilized powder dosed in milligrams — a 30 mg vial in the vendor format, against clinical courses of 10–60 mg/day. Those two units are not interconvertible without a published concentration for the liquid and a published peptide content for the powder, and neither exists. That is a practical consequence of the identity question rather than an answer to it, and it is the reason a protocol cannot be carried across.

Now the mechanism, and the honest observation is about the shape of the evidence rather than any one paper. Four studies of this preparation name four different pathways. Cerebral ischemia in rats: inhibition of MEK/ERK1/2 with CREB modulation and raised BDNF Ren 2021. Vascular dementia in mice: activation of PI3K/Akt with Bcl-2 upregulation Wu 2021. Neonatal hypoxic-ischemic encephalopathy in rats: activation of Wnt/beta-catenin reversing myelin damage Zhang 2024. An Alzheimer's mouse model: suppression of ferroptosis, with plasma Fe2+ and malondialdehyde falling and GPX4 protein and glutathione recovering Chen 2023. Note that one of them is an inhibition and the others are activations.

That is the signature of testing a mixture rather than a molecule, and it is not a criticism of any individual paper. Point any pathway assay at a preparation containing dozens of peptides and free amino acids and it will find something, because something in there moves something. What it cannot do is constrain the next experiment. A single molecule with a named target predicts what the second study will find; a hydrolysate does not. The one thing the four results share is that all of them are cell-survival signaling downstream of trophic factor receptors, which is at least consistent with the neurotrophic-mimetic claim — and is as far as the evidence reaches.

Cell, rodent, human — and where it stops

Unlike its better-known cousin, this preparation has a real, specific, dose-bearing rodent literature. That is the strongest thing about it.

Rodent, stroke. Adult male Sprague-Dawley rats, middle cerebral artery occlusion with reperfusion by suture insertion, CH-I 20 mg/kg intraperitoneally. Infarct volume and neuronal apoptosis fell on TTC and TUNEL, neurological scores improved, MEK/ERK/CREB signaling shifted and BDNF expression rose Ren 2021.

Rodent, vascular dementia. Kunming mice, bilateral common carotid artery occlusion. Learning and memory decline was attenuated, hippocampal CA1 apoptosis was reduced, Bcl-2 rose and PI3K/Akt was activated Wu 2021.

Rodent, Alzheimer's model — and note the route. Three-month-old male APP/PS1 double-transgenic mice against non-transgenic controls, experiments beginning at six months, 11.9 mg/kg/day by chronic oral gavage for 90 continuous days. Morris water maze trajectories simplified and escape latencies shortened; hippocampal neuronal morphology was restored; amyloid-beta and the p-tau/tau ratio fell; plasma Fe2+ and malondialdehyde fell; GPX4 protein and plasma glutathione recovered Chen 2023. That is an oral study of a product sold as an injectable, and it ran for three months.

Human. 102 children under three years old with provisional intellectual developmental disorder. Controls received standardized rehabilitation — physical, occupational, speech and cognitive training. The treatment group received 14 days of intravenous CH-I and then 76 days of oral derivatives on top of the same rehabilitation, with Gesell developmental scales and MRI at baseline and at 14, 30, 60 and 90 days. At 90 days, fine motor and adaptive functioning had improved significantly versus baseline (P<0.05). Adverse events occurred in 55.3% of the treatment group and 47.7% of controls, with none serious Hua 2025.

The obstacles, and the first one is about a preposition. (1) The reported improvement is versus baseline. Children under three get better at fine motor tasks over ninety days because they are children under three; that is what the Gesell scales are built to measure. The comparison that carries information is treatment against control, and it is the baseline comparison that the abstract reports. (2) Every rodent model is a lesion — artery occlusion, carotid ligation, neonatal hypoxia-ischemia, an amyloid transgenic Ren 2021 Wu 2021 Zhang 2024 Chen 2023. The mechanism on offer is rescue of neurons that are dying, and a healthy adult's cortex does not contain that population. (3) The route people buy is not the route most of the human exposure used: 76 of the 90 human days were oral Hua 2025, and the vendor format is a vial for injection. (4) The efficacy question in adults is untouched: there is no placebo-controlled adult trial of this preparation in the resolvable literature, and the pooled evidence for the same class in acute stroke found no benefit on death Ziganshina 2023.

Cerebroprotein Hydrolysate pharmacokinetics — how much of it actually gets in

This site's card says the half-life is not well characterized. That was true, and it is the one place where this product is now ahead of its better-known cousin — because somebody built the assay.

What was actually done. A group developed a robust quantitative LC-MS/MS method for the main peptides in CH-I, and ran a pharmacokinetic study in a neonatal hypoxic-ischemic encephalopathy rat model using a relative-exposure approach with a mixed-calibration-curve strategy. Their conclusion, in their own words: the transient exposure of peptides in vivo indicated that CH-I should exert neuroprotective effects through the ‘hit and run’ pattern Zhang 2024. That is the first real pharmacokinetic statement about any porcine brain hydrolysate, and it did not come from the product with the bigger reputation.

Why the phrase matters more than a number would. ‘Hit and run’ means exposure is brief and the effect is not. Set it beside the pharmacology: myelin repair through Wnt/beta-catenin Zhang 2024, ninety days of oral dosing changing amyloid and tau Chen 2023. None of that is a receptor being occupied while the drug is present. It is a short signal followed by a slow biological process, which means steady-state reasoning does not apply to this product — there is no accumulation to build toward and no trough to defend, and any dosing schedule justified by a half-life is justified by the wrong model.

What degrades it. Two fractions, two fates. The peptide fraction meets plasma aminopeptidases and endopeptidases; enzymatic hydrolysis reduces short peptides to free amino acids within minutes of an injection, which is precisely the transient exposure the assay measured. The free amino acid fraction is not cleared as a drug at all — it is consumed into the same pools as dietary protein. Neither process produces a concentration-time curve you could put a single half-life on, which is why the honest card entry is the one this site already carries.

The oral barrier, which this product uniquely has data against. Everything above says an oral dose should be destroyed: gastric acid, pancreatic proteases, brush-border peptidases, and a PepT1 transporter whose substrate range is di- and tripeptides. And yet 11.9 mg/kg/day by gavage for 90 days changed amyloid, tau, iron and glutathione in mice Chen 2023, and 76 of the 90 days of human exposure in the pediatric trial were oral Hua 2025. Either enough peptide survives to matter, or the effect is being carried by the amino acid and small-molecule fraction that survives digestion trivially. Nobody has distinguished those two explanations, and it is the most consequential open question about the product, because one of them makes it a drug and the other makes it an expensive protein supplement.

Route and dose. Intravenous or slow intravenous injection in clinical use, oral for the longer phase Hua 2025, intramuscular in vendor practice with no controlled data at all. Vendor format is a 30 mg lyophilized vial; clinical courses run 10–60 mg/day.

What would have to be true, and how you would know it was not

Four predictions. The second one comes straight out of the ferroptosis paper and names two markers nobody has ever connected to this product.

1. Against: an intact adult has nothing here for the drug to do. Four models, four pathways, and in every one of them the biology being corrected is cell death that is already under way — occluded artery, ligated carotid, amyloid burden Ren 2021 Wu 2021 Chen 2023. Rescue needs something to rescue. Score the MMSE and a MoCA before and after a course if you want the number; the prediction is that both sit inside their own test-retest noise, and that a null there is evidence about the substrate rather than about the dose.

2. The mechanistic prediction, and it is orderable: iron and oxidative markers. The Alzheimer's-model result was a ferroptosis result — plasma Fe2+ and malondialdehyde fell, GPX4 protein and plasma glutathione rose after 90 days of oral dosing Chen 2023. Ferroptosis is iron-dependent lipid peroxidation, so the human translation is two draws a consumer can actually order: a full iron panel with ferritin, and F2-isoprostane as the standard circulating index of lipid peroxidation. Baseline and 12 weeks. Prediction, stated as extrapolation: in a person whose baseline ferritin and F2-isoprostane are normal, neither moves — because the mouse result was a correction of a disease state, not a shift in a healthy one. A fall in F2-isoprostane in somebody with a raised baseline would be the first human evidence for the mechanism, and nobody has looked.

3. Against, on frequency of side effects rather than severity. In the one controlled human study, adverse events occurred in 55.3% of treated children against 47.7% of controls, none serious Hua 2025. Both arms are high because the population is toddlers in intensive rehabilitation, but the direction is what a user should expect. Prediction: minor adverse events on a course are common rather than rare, and anyone reporting a clean run is reporting incomplete records. Log daily, including the days nothing happens.

4. The identity prediction, and it is the only one here that can be settled by somebody else's laboratory. Run the published CH-I peptide assay Zhang 2024 on a Cerebrolysin ampoule. Prediction: the two chromatograms overlap substantially in their major peaks and differ in relative abundances by more than the lot-to-lot variation of either. That would make them the same class and not the same product — which is what this page argues from the written record, and it would be the first time anybody tested it.

What nobody has tested yet

Five experiments. The first would resolve what the product is; the second decides whether it can be swallowed.

1. Nobody has named the peptides. The pharmacokinetic study quantifies ‘the main peptides in CH-I’ Zhang 2024, and the sequences of those analytes are not part of the accessible international record. The molecules that define this product are therefore unpublished, even though somebody has an assay for them. Publishing that list would convert a mixture into a defined preparation and would let every other laboratory check a vial.

2. Nobody has separated the peptide fraction from the amino acid fraction and tested them apart. This is the experiment that decides what the product is. Take the same preparation, split it by size, and run both halves plus the whole in one of the existing rodent models at matched mass Ren 2021. If the peptide fraction carries the effect, this is a drug. If the amino acid fraction does, it is nutrition delivered expensively by needle. Nobody has run it in either of these products' entire histories.

3. There is no placebo-controlled adult trial. The human evidence resolvable here is in children under three, against active rehabilitation, reported against baseline Hua 2025. Adults are the people buying it, and they have never been studied with this preparation under this name.

4. Nobody has run the oral form in adults at all. A 90-day oral gavage study changed pathology in mice Chen 2023 and 76 of 90 human days were oral Hua 2025, yet the adult market is served by an injectable vial. If oral works, the entire injection protocol — and its needles, its sterility risk and its cost — is unnecessary. That is a large practical question with an easy trial design and no answer.

5. Nobody has checked whether the harm signal transfers. The pooled Cochrane analysis of the same class in acute stroke found a non-fatal serious adverse event risk ratio of 2.39 Ziganshina 2023. Whether that belongs to this preparation too depends entirely on the identity question, and no pharmacovigilance comparison of the two products has been published.

Cerebroprotein Hydrolysate — its own safety story, not its class's

Everything in the class block above applies to any injected peptide. What follows is specific to this one, and it turns almost entirely on a question the previous sections could not close: which product is in the vial, and whose safety record it therefore carries.

1. The safety argument has two branches and neither is comfortable. If this preparation and Cerebrolysin are the same class — and their own literature defines them in the same words Wu 2021 Zhang 2024 — then the Cochrane finding of non-fatal serious adverse events at a risk ratio of 2.39, 95% CI 1.10 to 5.23 Ziganshina 2023 applies here as the most conservative reading. If they are not the same, then this product's entire published safety database is the one controlled trial above — 102 children, none of them adults, no serious events Hua 2025. Inherit a harm signal, or own almost no safety data. Both branches argue for caution and neither argues for confidence.

2. The buying error is the format, and it goes in one direction. Cerebrolysin is a liquid ampoule concentrate; this is a lyophilized powder. A vial labeled Cerebrolysin containing 30 mg of powder is cerebroprotein hydrolysate. The safety consequence rather than the pedantic one: somebody carrying a milliliter protocol across to a milligram vial has no conversion factor, because no published peptide concentration exists for either product. They are not estimating badly — they are estimating with nothing.

3. What a lyophilized powder adds to the porcine-origin question. The immunological hazard of pig-derived material is the same one it always is, and this site's Cerebrolysin page sets it out. The part specific to a powder is reconstitution: the buyer, not a manufacturer, chooses the diluent, the volume and the storage, and a peptide mixture reconstituted into bacteriostatic water and kept for weeks has a microbiological and a degradation clock running that a sealed liquid ampoule does not. No stability datum for a reconstituted 30 mg vial has been published, so nobody can tell you how long the peptides last once the stopper is pierced — and for a product whose whole identity is its peptide distribution, that is not a housekeeping question.

4. Anti-doping, and the answer is not the same as for a research chemical. Cerebroprotein hydrolysate is a licensed medicine in the country where the trials on this page were run and where the product is manufactured Hua 2025, which is the specific fact that keeps it out of WADA's S0 category for non-approved substances — unlike several other compounds on this shelf. The rule that does apply is about method: intravenous infusions or injections exceeding 100 mL per 12-hour period are prohibited outside hospital treatment. A reconstituted 30 mg vial is nowhere near that volume. Check the current Prohibited List rather than this paragraph.

5. What ‘well tolerated’ is standing on. One controlled trial, 102 participants, all under three years old, 90 days, adverse events in over half of both arms and none serious Hua 2025. That is a real result and it is a small one. It cannot exclude an event occurring in one adult per hundred, and it says nothing about repeated annual courses, which is how people on this site actually use it.

Sources read for this page

• Zhang T, Liu Y, Wang G, Wang Z, Fan X, Shen Y, Liu W, Zhang D, He L, Xie L, Yu T, Liang Y. Evidence of the 'hit and run' characteristics of Cerebroprotein Hydrolysate-I in the treatment of neonatal HIE based on pharmacokinetic and pharmacological studies. International Immunopharmacology 2024;143(Pt 3):113580 · PMID 39547013
• Ren Y, Ma X, Wang T, Cheng B, Ren L, Dong Z, Liu H. The Cerebroprotein Hydrolysate-I Plays a Neuroprotective Effect on Cerebral Ischemic Stroke by Inhibiting MEK/ERK1/2 Signaling Pathway in Rats. Neuropsychiatric Disease and Treatment 2021;17:2199-2208 · PMID 34262280
• Wu X, Liu Y, Zhu L, Wang Y, Ren Y, Cheng B, Ren L, Ge K, Li H. Cerebroprotein Hydrolysate-I Inhibits Hippocampal Neuronal Apoptosis by Activating PI3K/Akt Signaling Pathway in Vascular Dementia Mice. Neuropsychiatric Disease and Treatment 2021;17:2359-2368 · PMID 34305399
• Chen M, Song W, Chen Z, Shi X, Wang X, Li R, Hao H, Chen W. Cerebroprotein hydrolysate attenuates neurodegenerative changes in Alzheimer's mice model via ferroptosis pathway. Frontiers in Pharmacology 2023;14:1177503 · PMID 37153800
• Hua R, Hou Y, Yang L, Gao H, Yang F, Liu W, Jiang J, Wang B, Wu D. Efficacy and Safety of Cerebroprotein Hydrolysate I Combined with Rehabilitation Training in the Treatment of Provisional Intellectual Developmental Disorder in Children. Neuropsychiatric Disease and Treatment 2025;21:2067 · PMID 40964073
• Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K. Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2023;10:CD007026 · PMID 37818733

Cerebroprotein Hydrolysate — safety, predicted from mechanism

Cerebroprotein Hydrolysate — interference & stacking

Bloodwork to run alongside Cerebroprotein Hydrolysate

Baseline first, then again at 8–12 weeks.

The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.

Check results you already have → · All 103 markers A–Z

Cerebroprotein Hydrolysate — frequently asked questions

What Cerebroprotein Hydrolysate is used for

Cerebroprotein Hydrolysate appears under 1 goal in the goal router.

Related Cognitive & Mood compounds

← Explore the full Protocol Vault

↑ Back to on this page